Skip to main content

Table 2 (abstract P178). Estimated differences in CFB MMD at 12 weeks in chronic migraine. Values <0 favor eptinezumab. ‘Significance’ at 0.05 threshold should be judged by 95% intervals not crossing 0 and is indicated by an asterisk (*)

From: 16th European Headache Congress 2022 meeting abstracts